Ligand (LGND) Form 4: Director Disposes of 10,000 Shares at ~$171
Rhea-AI Filing Summary
Jason Aryeh, a director of Ligand Pharmaceuticals (LGND), reported the sale of 10,000 shares of Ligand common stock on 09/23/2025. The sales occurred in multiple transactions at weighted-average prices reported in three groupings: $170.4051 (range $169.6625–$170.6600), $170.9643 (range $170.6850–$171.6050), and $171.9237 (range $171.7250–$172.2400).
After these transactions Mr. Aryeh directly beneficially owned between 69,289 and 74,871 shares across the reported lines and retains indirect holdings of 51,594 shares through funds managed by JALAA Equities, LP/JLV Investments, LP and 5,025 shares held by a trust. The Form 4 was signed on 09/24/2025 by an attorney-in-fact.
Positive
- Timely and transparent disclosure of insider sales with weighted-average prices and offered breakdown on request
- Clear attribution of indirect holdings via JALAA Equities, JLV Investments and a trust
Negative
- Insider sold 10,000 shares on 09/23/2025, representing realized liquidation of direct holdings
- Direct beneficial ownership was reduced to reported levels (as low as 69,289 on one reported line)
Insights
TL;DR: Director sold 10,000 shares on 09/23/2025 across weighted-average prices near $170–$172; indirect holdings remain material.
The filing shows routine insider disposition rather than acquisition activity. Total shares sold equal 10,000, executed in multiple trades with disclosed weighted-average prices and price ranges, which provides granular transparency about execution levels. Direct beneficial ownership lines after the sales are reported as 74,871; 70,243; and 69,289 shares on separate lines, while indirect ownership via funds and a trust totals 56,619 shares. For investors, this is a disclosure of insider liquidity but does not itself quantify impact on company fundamentals or signal change in control.
TL;DR: Filing complies with Section 16 disclosure; sales were disclosed promptly and include explanatory footnotes on weighted-average pricing.
The Form 4 includes detailed footnotes clarifying that reported prices are weighted averages from multiple trades and offers to provide per-trade quantities upon request, which strengthens compliance posture. It also clarifies beneficial ownership attribution through investment funds where Mr. Aryeh is a partner, consistent with Rule 16a-1. The filing appears procedural and transparent, with no additional governance events disclosed.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 4,418 | $170.4051 | $753K |
| Sale | Common Stock | 4,628 | $170.9643 | $791K |
| Sale | Common Stock | 954 | $171.9237 | $164K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (4)
- F1. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $169.6625 to $170.6600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $170.6850 to $171.6050. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $171.7250 to $172.2400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4. All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds.
AI-generated analysis. How Rhea-AI works. Not financial advice.
